<DOC>
	<DOC>NCT01492192</DOC>
	<brief_summary>The goal of this clinical research study is to look at 2 new methods of scanning and see whether they can help researchers predict which tumours will respond to drugs that attack tumour blood supply.</brief_summary>
	<brief_title>RGD-PET-CT in Cancer Angiogenesis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>1. Patients should have advanced or metastatic RCC confirmed by histological diagnosis 2. Patients considered suitable for therapy with TKI for RCC according to responsible clinician 3. Measurable tumour according to RECIST v1.1 criteria 4. Standard staging CT scan performed within 28 days of first research scan 5. The patient has not received chemotherapy, radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to recruitment 6. Age â‰¥18 years 7. Adequate renal function (creatinine &lt;1.25xULN) 8. Patient is able to tolerate and comply with scanning procedure 9. Patient is not lactating or pregnant 10. Absence of any psychological, familial, sociological or geographical condition which in the opinion of the Investigator may potentially hamper compliance with the study protocol and followup schedule; those conditions should be discussed with the patient before registration in the trial 11. Able and willing to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>PET-CT</keyword>
	<keyword>Perfusion-CT</keyword>
</DOC>